Chugai Pharmaceutical Co., Ltd. (4519) Press Release
Notice Regarding Discontinuation of Development of GYM329 (emugrobart) for Obesity, Return of License and Resumption of Development for SMA
Earlier from Chugai Pharmaceutical
- Three Chugai Researchers Behind the Discovery of Hemlibra for Hemophilia A Receive Prestigious U.S. Lasker Award, One of the World’s Most Respected Scientific Honors
- Chugai and GSK Sign Exclusive License Agreement for Anti-Dengue Virus Antibody AID351
- Chugai Announces 2026 2nd Quarter Results
- CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the six months ended June 30, 2026)